Abbott India Limited (ABBOTINDIA.NS)
INR 28755.5
(2.3%)
INR 28755.5
(2.3%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 14.94 Billion INR | 9.34% |
| 2022 | 13.66 Billion INR | -2.66% |
| 2021 | 14.04 Billion INR | 13.41% |
| 2020 | 12.38 Billion INR | 11.04% |
| 2019 | 11.15 Billion INR | 19.61% |
| 2018 | 9.32 Billion INR | 28.88% |
| 2017 | 7.23 Billion INR | 6.88% |
| 2016 | 6.76 Billion INR | 31.07% |
| 2015 | 5.16 Billion INR | 18.42% |
| 2014 | 4.36 Billion INR | 42.46% |
| 2013 | 3.06 Billion INR | 17.63% |
| 2012 | 2.6 Billion INR | 1.62% |
| 2011 | 2.56 Billion INR | 72.99% |
| 2010 | 1.48 Billion INR | 32.95% |
| 2009 | 1.11 Billion INR | -13.88% |
| 2008 | 1.29 Billion INR | 30.13% |
| 2007 | 993.6 Million INR | 4.93% |
| 2006 | 946.9 Million INR | 0.81% |
| 2005 | 939.3 Million INR | -24.15% |
| 2004 | 1.23 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 FY | 14.94 Billion INR | 9.34% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 14.07 Billion INR | 0.0% |
| 2023 Q4 | 14.94 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q4 | 13.66 Billion INR | 0.0% |
| 2022 Q2 | 13.85 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 13.66 Billion INR | -2.66% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 14.04 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 14.04 Billion INR | 13.41% |
| 2021 Q2 | 13.11 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 12.38 Billion INR | 11.04% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 12.38 Billion INR | 0.0% |
| 2020 Q2 | 12.17 Billion INR | 0.0% |
| 2019 Q4 | 11.15 Billion INR | 0.0% |
| 2019 FY | 11.15 Billion INR | 19.61% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 10.43 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q2 | 9.5 Billion INR | 0.0% |
| 2018 FY | 9.32 Billion INR | 28.88% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q4 | 9.32 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 7.16 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 7.23 Billion INR | 6.88% |
| 2017 Q4 | 7.23 Billion INR | 0.0% |
| 2016 Q2 | 5.36 Billion INR | 0.0% |
| 2016 Q4 | 6.76 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 FY | 6.76 Billion INR | 31.07% |
| 2016 Q3 | - INR | -100.0% |
| 2015 FY | 5.16 Billion INR | 18.42% |
| 2015 Q2 | 3.81 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q4 | 5.16 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2014 Q4 | 4.36 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 4.36 Billion INR | 42.46% |
| 2014 Q2 | 3.11 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2013 FY | 3.06 Billion INR | 17.63% |
| 2013 Q4 | 3.06 Billion INR | 0.0% |
| 2013 Q2 | - INR | -100.0% |
| 2013 Q1 | 3.03 Billion INR | 26.75% |
| 2012 Q3 | 2.6 Billion INR | 0.0% |
| 2012 Q4 | 2.39 Billion INR | -7.86% |
| 2012 FY | 2.6 Billion INR | 1.62% |
| 2011 Q3 | 2.56 Billion INR | 0.0% |
| 2011 FY | 2.56 Billion INR | 72.99% |
| 2010 FY | 1.48 Billion INR | 32.95% |
| 2009 FY | 1.11 Billion INR | -13.88% |
| 2008 FY | 1.29 Billion INR | 30.13% |
| 2007 FY | 993.6 Million INR | 4.93% |
| 2006 FY | 946.9 Million INR | 0.81% |
| 2005 FY | 939.3 Million INR | -24.15% |
| 2004 FY | 1.23 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Cipla Limited | 59.15 Billion INR | 74.734% |
| Gland Pharma Limited | 19.37 Billion INR | 22.855% |
| GlaxoSmithKline Pharmaceuticals Limited | 17.96 Billion INR | 16.787% |
| Kopran Limited | 2.52 Billion INR | -493.092% |
| Marksans Pharma Limited | 5.95 Billion INR | -151.173% |
| NGL Fine-Chem Limited | 929.03 Million INR | -1508.759% |
| Pfizer Limited | 6.33 Billion INR | -136.024% |
| Sanofi India Limited | 6.99 Billion INR | -113.636% |
| SMS Pharmaceuticals Limited | 4.97 Billion INR | -200.263% |
| TTK Healthcare Limited | 1.99 Billion INR | -648.513% |